In vitro study | In Vitro, JNJ-26481585 effectively inhibits a group of recombinant HDAC enzymes, the most effective inhibition of HDAC1,IC50 0.11 nM, in addition to inhibit other family members such as HDAC2, 4, 10 and 11 when the effect is slightly lower, the IC50 was 0.33 nM, 0.64 nM, 0.46 nM and 0.37 nM, respectively. JNJ-26481585 acts on solid tumors and blood cancer cell lines, such as lung, breast, colon, prostate, brain, and ovarian cancer cell lines, with an IC50 of 3.1 to 246 nM, with broad-spectrum anti-proliferative activity, when acting on a variety of human cancer cell lines, the JNJ-26481585 effect is better than that of Vorinostat, R306465, Panobinostat, CRA-24781, and Mocetinostat. Recent studies have shown that JNJ-26481585 promotes bone marrow cancer cell death at low nanomolar concentrations by depleting Mcl-1 and inducing Hsp72 production. |